ThromboGenics Establishes Level 1 ADR Program for US Investors

        ThromboGenics Establishes Level 1 ADR Program for US Investors

  PR Newswire

  LEUVEN, Belgium, September 30, 2013

LEUVEN, Belgium, September 30, 2013 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company
focused on developing and commercializing innovative ophthalmic medicines,
announces that it has established a sponsored Level 1 American Depositary
Receipt (ADR) program. Trading of the ADRs commences today on the US over the
counter (OTC) market under the ticker TBGNY.

ThromboGenics' ADRs are US dollar negotiable certificates with each ADR
representing half of one ordinary share of the Company. J.P. Morgan has been
appointed as the depositary bank for the ThromboGenics' ADR program.

ADR effective date: September 30, 2013

Symbol: TBGNY

   Traded: OTC

   Ratio 2 ADRs: 1 Ordinary Share

   CUSIP: 886003 10 2

   Local ISIN: BE0003846632

   Country of incorporation: Belgium

   Industry: Biopharmaceutical

   Depositary: JPMorgan Chase Bank, N.A.

   Custodian: BNP Paribas, Belgium

For questions related to the ThromboGenics ADR Program, please contact J.P.
Morgan shareholder services:

J.P. Morgan Depositary Bank

1 Chase Manhattan Plaza, Floor 58

New York, NY 10005

In the U.S.: (866) JPM-ADRS 

Outside the U.S.: (+1 866 576-2377)

Or visit J.P. Morgan Depositary Receipts Services at http://www.adr.com .

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA ^® (ocriplasmin), has been approved by the US
FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA ^® outside the United States. Under this
agreement, ThromboGenics could receive up to a total of €375 million in
up-front and milestone payments. It will receive significant royalties from
Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend to share the
costs equally of developing JETREA ^® for a number of new vitreoretinal
indications.

In Europe, JETREA ^® is approved for the treatment of vitreomacular traction
(VMT), including when associated with macular hole of diameter less than or
equal to 400 microns. Alcon has launched JETREA ^® in the UK, Germany,
Denmark, Norway, Finland and Sweden. 

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.  No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

Contact: For further information please contact: ThromboGenics, Wouter
Piepers, Global Head of Corporate Communications, +32 16 75 13 10 / +32 478 33
56 32, Wouter.piepers@thrombogenics.com; Dr. Patrik De Haes, CEO, +32 16 75 13
10, Patrik.dehaes@thrombogenics.com; Chris Buyse, CFO, +32 16 75 13 10,
Chris.buyse@thrombogenics.com; Citigate Dewe Rogerson, David Dible/ Sita Shah,
Tel: +44 20 7638 9571, sita.shah@citigatedr.co.uk ; The Trout Group (US
investor relations), Todd James/ Simon Harnest, Tel: +1 646 378 2926,
tjames@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.